ICX 301
Alternative Names: ICX-301Latest Information Update: 21 Sep 2023
At a glance
- Originator Incurix
- Class Antineoplastics; Small molecules
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 31 Aug 2023 Preclinical trials in Prostate cancer (Hormone refractory) in South Korea (PO)
- 31 Aug 2023 Pharmacodynamics data from the preclinical trial in Prostate cancer released by Incurix (Incurix pipeline; September 2023)
- 31 Aug 2023 Incurix plans a lead optimization study in 2nd half of 2024 (Incurix pipeline; September 2023).